Maxime Verhoeven

91 TCZ vs. TCZ+MTX; prevention of radiographic progression in RA SUPPLEMENTARY FILE Supplementary Data S1: Search strategy The intent of the current study will be to enhance knowledge of joint-sparing effects in RA patients treated with different TCZ-regimens. PICO question: P= RA patients I=  treatment with tocilizumab monotherapy (intravenously, without methotrexate) C= treatment with tocilizumab combination therapy (intravenously, with methotrexate) O= radiographic progression Selection criteria: 1. Randomized controlled trial 2. Patients were randomly allocated to treatment arm 3. Tocilizumab treatment in at least on arm with monotherapy as well as one arm with combination therapy with MTX (TCZ+MTX) 4. Radiographs performed at baseline and after 2 years 5. RA patients, according to the 2010 American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) criteria or 1987 revised ACR criteria 6. Active disease at baseline 7. Aged above 18 years Supplementary Data S2: Included studies ACTRAY: Design: International, multicenter, 2 arm randomized (TCZ+MTX vs. TCZ+Placebo) double blind placebo controlled parallel group study of 2 year duration with possible treatment adjustments at weeks 24, 36, 52, 64, 76 , 88 and 100. Inclusion: Men and women, ≥18 years of age, body weight ≤150kg, with moderate to severe RA, experiencing active disease, and had responded inadequately to MTX as defined by DAS28 >4.4 at baseline. At screening the DAS28 was equal or greater than 4.0. 5